Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01520389 · ClinicalTrials.gov registry record · Phase 1
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
A Phase 1 study, sponsored by Merrimack Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 112
- Enrollment target
NCT01520389: Completed Phase 1 study, sponsored by Merrimack Pharmaceuticals.
NCT01520389 is a Phase 1 study that has completed, run by Merrimack Pharmaceuticals. The registered enrollment target is 112 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01520389, a Phase 1 study, has completed, sponsored by Merrimack Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 112 participants
- Enrollment target
Study Summary
This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design, evaluating MM-151 at varying dose levels and frequencies, and subsequently in combination with irinotecan.
Interventions
- DRUG MM-151
- DRUG MM-151 + irinotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2012-01 |
| Est. Completion | 2016-01 |
| Phase | Phase 1 |
What the finished NCT01520389 record still lists
NCT01520389 is an interventional study that assigns participants to a tested intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% higher).
The record links to 0 conditions, and to 2 interventions - of which MM-151 is the first listed.
NCT01520389 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01520389 about?
NCT01520389 is a clinical study titled "Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment". This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design, evaluating MM-151 at varying dose levels and frequencies, and subsequently in combination with irinotecan.
What is the current status of trial NCT01520389?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 112 participants. The study started on 2012-01. Estimated completion is 2016-01.
What interventions are being tested in trial NCT01520389?
The interventions under investigation include: MM-151 (DRUG), MM-151 + irinotecan (DRUG).
Who is sponsoring clinical trial NCT01520389?
This trial is sponsored by Merrimack Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01520389's enrollment target sits among peer trials
112 508th of 2000 higher than 1,489 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04511013 · 112 participants · Phase 2
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- NCT04551560 · 112 participants · NA
Stress and Congestive Heart Failure
- NCT04872166 · 112 participants · Phase 1
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- NCT05024773 · 112 participants · Phase 3
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia